FFA
BPMC

Freedman Financial Associates’s Blueprint Medicines BPMC Stock Holding History

Freedman Financial Associates’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-150
Closed -$10K – 54
2022
Q1 		$10K Hold
150
– – 0.01% 355
2021
Q4 		$16K Hold
150
– – 0.01% 305
2021
Q3 		$15K Hold
150
– – 0.01% 313
2021
Q2 		$13K Hold
150
– – 0.01% 321
2021
Q1 		$15K Hold
150
– – 0.01% 323
2020
Q4 		$17K Buy
+150
New +$15.8K 0.02% 302

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Freedman Financial Associates's BPMC Position: Q2 2022 in Review

Freedman Financial Associates sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 150 shares — an estimated $10K sold.

Freedman Financial Associates first reported a position in BPMC in Q4 2020 and held it in 6 quarters. The position peaked at $17K in Q4 2020. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

  • Freedman Financial Associates reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 150 Blueprint Medicines shares in Q2 2022, an estimated $10K.
  • Freedman Financial Associates first reported a position in Blueprint Medicines in Q4 2020 and held it in 6 quarters.
  • Freedman Financial Associates's Blueprint Medicines position peaked at $17K in Q4 2020.
  • 237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.